KIORA PHARMACEUTICALS INC (KPRX) Stock Fundamental Analysis
USA - NASDAQ:KPRX - US49721T5074 - Common Stock
2.5496 USD
+0.1 (+4.07%)
Taking everything into account, KPRX scores 3 out of 10 in our fundamental rating. KPRX was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of KPRX is average, but there are quite some concerns on its profitability. KPRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year KPRX has reported negative net income.
In the past year KPRX has reported a negative cash flow from operations.
KPRX had negative earnings in 4 of the past 5 years.
KPRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of KPRX (-37.51%) is comparable to the rest of the industry.
With a Return On Equity value of -54.15%, KPRX perfoms like the industry average, outperforming 53.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.51% | ||
| ROE | -54.15% | ||
| ROIC | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KPRX has more shares outstanding
Compared to 5 years ago, KPRX has more shares outstanding
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -6.07, we must say that KPRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.07, KPRX is doing worse than 62.50% of the companies in the same industry.
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.07 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
KPRX has a Current Ratio of 7.76. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.76, KPRX is doing good in the industry, outperforming 76.04% of the companies in the same industry.
KPRX has a Quick Ratio of 7.76. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
KPRX has a better Quick ratio (7.76) than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.76 | ||
| Quick Ratio | 7.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 68.88% over the past year.
The Revenue for KPRX has decreased by -100.00% in the past year. This is quite bad
The Revenue has been growing by 42.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)68.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, KPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.29% on average per year.
Based on estimates for the next years, KPRX will show a very strong growth in Revenue. The Revenue will grow by 32.09% on average per year.
EPS Next Y-347.64%
EPS Next 2Y-107.48%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue Next Year-91.05%
Revenue Next 2Y-78.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
KPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as KPRX's earnings are expected to decrease with -59.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-107.48%
EPS Next 3Y-59.01%
5. Dividend
5.1 Amount
KPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KPRX (10/29/2025, 2:22:25 PM)
2.5496
+0.1 (+4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners20.54%
Inst Owner Change0%
Ins Owners3.05%
Ins Owner Change0%
Market Cap8.75M
Revenue(TTM)N/A
Net Income(TTM)-11982300
Analysts82.5
Price Target11.22 (340.07%)
Short Float %0.02%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.2%
Min EPS beat(2)12.49%
Max EPS beat(2)23.91%
EPS beat(4)2
Avg EPS beat(4)-13.23%
Min EPS beat(4)-85.38%
Max EPS beat(4)23.91%
EPS beat(8)4
Avg EPS beat(8)61.73%
EPS beat(12)7
Avg EPS beat(12)44.89%
EPS beat(16)9
Avg EPS beat(16)23.2%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.4 | ||
| P/tB | 0.57 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.91
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-2.28
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS0
BVpS6.45
TBVpS4.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.51% | ||
| ROE | -54.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 109.4% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.76 | ||
| Quick Ratio | 7.76 | ||
| Altman-Z | -6.07 |
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.89%
EPS Next Y-347.64%
EPS Next 2Y-107.48%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%-100%
Revenue Next Year-91.05%
Revenue Next 2Y-78.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y-295.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.91%
OCF growth 3YN/A
OCF growth 5YN/A
KIORA PHARMACEUTICALS INC / KPRX FAQ
What is the ChartMill fundamental rating of KIORA PHARMACEUTICALS INC (KPRX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KPRX.
What is the valuation status of KIORA PHARMACEUTICALS INC (KPRX) stock?
ChartMill assigns a valuation rating of 0 / 10 to KIORA PHARMACEUTICALS INC (KPRX). This can be considered as Overvalued.
Can you provide the profitability details for KIORA PHARMACEUTICALS INC?
KIORA PHARMACEUTICALS INC (KPRX) has a profitability rating of 1 / 10.
What is the expected EPS growth for KIORA PHARMACEUTICALS INC (KPRX) stock?
The Earnings per Share (EPS) of KIORA PHARMACEUTICALS INC (KPRX) is expected to decline by -347.64% in the next year.